Reading this on a mobile device? Try our optimized mobile version here:

January 4, 2013
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • PET/CT better than standard tests for advanced breast cancer
    FDG-PET/CT performed better than standard imaging, including bone scans, chest radiography and CT scans, in accurately detecting lesions in the chest, abdomen and bones in patients with locally advanced breast cancer, according to a study published in the Journal of Nuclear Medicine. FDG-PET/CT also modified disease staging in 52% of patients, allowing for an improvement in treatment. FDG-PET/CT identified distant metastases in 37% of patients, compared with 24% for conventional imaging, the study said. (free registration) (1/3) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Phase II trials of cardiac imaging agent BFPET underway
    FluoroPharma said Phase II trials of its BFPET imaging agent for chronic coronary artery disease have started at Massachusetts General Hospital. In this current study, the fluorine-18-labeled tracer will be compared with Rb-82 and/or other SPECT agents such as sestamibi. Yahoo/Zacks (1/3) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Lantheus extends SPECT agents deal with Japanese firm
    Lantheus Medical Imaging has renewed its long-term licensing and distribution deal with Fujifilm RI Pharma covering SPECT imaging agents Cardiolite and Neurolite. As part of the 10-year deal, which took effect Jan. 1, Lantheus will keep providing FRI with the agents in finished form for distribution in Japan. Lantheus will also supply raw materials for developing and marketing in unit dose format. (free registration) (1/3) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Days of plenty are over for biomedical research
    As NIH funding for biomedical research has dwindled, scientists are turning to big drugmakers and disease-focused foundations, shifting the focus from basic to translational research, writes Luke Timmerman. The result could be a slew of new drugs, devices and diagnostics over the next decade, he writes. But moving too far away from basic research could bring missed opportunities for "a whole series of bigger breakthroughs that can come only from asking basic, open-ended research questions about how genes, cells, and lower organisms work," he writes. Xconomy (12/31) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Polish researchers aim for large-scale production of isotopes
    Researchers at POLATOM labs in Swierk, Poland, have developed a new production line for the radioisotopes yttrium-90 and lutetium-177, which were developed by scientists at the Polish National Centre for Nuclear Research for use in treating cancer. Efforts to start pilot production of the isotopes are underway. "The new radioisotope preparations have been named by us Itrapol and Lutapol. They are precursors necessary to produce radiopharma­ceuticals," said Radioisotope Centre POLATOM Director Proxy for Scientific Matters Renata Mikolajczak. MTB Europe/News release (1/3) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Obama signs "fiscal cliff" bill delaying SGR fee cuts
    President Barack Obama on Wednesday signed the American Taxpayer Relief Act of 2012, popularly known as the "fiscal cliff" legislation. The measure delays for one year an almost 27% cut in doctor fees under the Medicare sustainable growth rate formula. The bill, however, compensates for the SGR fix with budget cuts in other areas, including $800 million in fee cuts in radiology and $300 million in cuts in radiation oncology. (free registration) (1/3) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

Beware the fury of a patient man."
--John Dryden,
British poet, critic and playwright

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information